Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

Published on 2021-04-012022-10-05
Journal: International Journal of Infectious Diseases

[저자] Zarir F. Udwadia, Hanmant Barkate, Saiprasad Patil, Shabbir Rangwala, Wen Wu, Cynthia F. Caracta, Monika Tandon

[Category] SARS, 임상,

[DOI] 10.1016/j.ijid.2021.02.028

[Article Type] Correspondence

[Source] Sciencedirect

All Keywords
【제목키워드】 Open-label, Favipiravir, Randomized, response, RNA-dependent RNA polymerase, multicenter, inhibitor, Phase 3, Mild-to-moderate,